Is This Disturbing Trend Bad News for Eli Lilly in the Billion-Dollar Obesity Drug Market?

Eli Lilly's new oral weight loss drug Foundayo is showing concerning early signs with flat prescription growth over five weeks post-launch, significantly trailing Novo Nordisk's oral Wegovy. However, analysts note that Foundayo's slower start may be temporary due to later pharmacy coverage and being a new drug formulation, while Lilly maintains a strong 60% U.S. market share and deep pipeline in the rapidly growing weight loss drug market.